Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

A novel p53 mutational hotspot in skin tumors from UV-irradiated Xpc mutant mice alters transactivation functions

Abstract

A mutation in codon 122 of the mouse p53 gene resulting in a T to L amino acid substitution (T122→L) is frequently associated with skin cancer in UV-irradiated mice that are both homozygous mutant for the nucleotide excision repair (NER) gene Xpc (Xpc−/−) and hemizygous mutant for the p53 gene. We investigated the functional consequences of the mouse T122→L mutation when expressed either in mammalian cells or in the yeast Saccharomyces cerevisiae. Similar to a non-functional allele, high expression of the T122→L allele in p53−/− mouse embryo fibroblasts and human Saos-2 cells failed to suppress growth. However, the T122→L mutant p53 showed wild-type transactivation levels with Bax and MDM2 promoters when expressed in either cell type and retained transactivation of the p21 and the c-Fos promoters in one cell line. Using a recently developed rheostatable p53 induction system in yeast we assessed the T122→L transactivation capacity at low levels of protein expression using 12 different p53 response elements (REs). Compared to wild-type p53 the T122→L protein manifested an unusual transactivation pattern comprising reduced and enhanced activity with specific REs. The high incidence of the T122→L mutant allele in the Xpc−/− background suggests that both genetic and epigenetic conditions may facilitate the emergence of particular functional p53 mutations. Furthermore, the approach that we have taken also provides for the dissection of functions that may be retained in many p53 tumor alleles.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Ashcroft M, Vousden KH . 1999 Oncogene 18: 7637–7643

  • Aurelio ON, Kong XT, Gupta S, Stanbridge EJ . 2000 Mol. Cell. Biol. 20: 770–778

  • Blagosklonny MV, Giannakakou P, Romanova LY, Ryan KM, Vousden KH, Fojo T . 2001 Carcinogenesis 22: 861–867

  • Brachmann RK, Vidal M, Boeke JD . 1996 Proc. Natl. Acad. Sci. USA 93: 4091–4095

  • Brash DE, Ponten J . 1998 Cancer Surv. 32: 69–113

  • Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, Leffell DJ . 1996 J. Investig. Dermatol. Symp. Proc. 1: 136–142

  • Campomenosi P, Monti P, Aprile A, Abbondandolo A, Frebourg T, Gold B, Crook T, Inga A, Resnick MA, Iggo R, Fronza G . 2001 Oncogene 20: 3573–3579

  • Cheo DL, Meira LB, Burns DK, Reis AM, Issac T, Friedberg EC . 2000 Cancer Res. 60: 1580–1584

  • Crook T, Brooks LA, Crossland S, Osin P, Barker KT, Waller J, Philp E, Smith PD, Yulug I, Peto J, Parker G, Allday MJ, Crompton MR, Gusterson BA . 1998 Oncogene 17: 1681–1689

  • el-Deiry WS . 1998 Semin. Cancer Biol. 8: 345–357

  • el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B . 1992 Nat. Genet. 1: 45–49

  • Elkeles A, Juven-Gershon T, Israeli D, Wilder S, Zalcenstein A, Oren M . 1999 Mol. Cell. Biol. 19: 2594–2600

  • Espinosa JM, Emerson BM . 2001 Mol. Cell 8: 57–69

  • Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher IM, Bron L, Benhattar J, Tada M, van Meir EG, Estreicher A, Iggo RD . 1995 Proc. Natl. Acad. Sci. USA 92: 3963–3967

  • Flaman JM, Robert V, Lenglet S, Moreau V, Iggo R, Frebourg T . 1998 Oncogene 16: 1369–1372

  • Frazier MW, He X, Wang J, Gu Z, Cleveland JL, Zambetti GP . 1998 Mol. Cell. Biol. 18: 3735–3743

  • Freeman J, Schmidt S, Scharer E, Iggo R . 1994 EMBO J. 13: 5393–5400

  • Ginsberg D, Mechta F, Yaniv M, Oren M . 1991 Proc. Natl. Acad. Sci. USA 88: 9979–9983

  • Gorospe M, Cirielli C, Wang X, Seth P, Capogrossi MC, Holbrook NJ . 1997 Oncogene 14: 929–935

  • Gottifredi V, Shieh S, Taya Y, Prives C . 2001 Proc. Natl. Acad. Sci. USA 98: 1036–1041

  • Hainaut P, Hollstein M . 2000 Adv. Cancer Res. 77: 81–137

  • Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, Hainaut P . 1999 Hum. Mutat. 14: 1–8

  • Hill LL, Ouhtit A, Loughlin SM, Kripke ML, Ananthaswamy HN, Owen-Schaub LB . 1999 Science 285: 898–900

  • Holmquist GP, Gao S . 1997 Mutat. Res. 386: 69–101

  • Hussain SP, Harris CC . 1999 Mutat. Res. 428: 23–32

  • Inga A, Monti P, Fronza G, Darden T, Resnick MA . 2001 Oncogene 20: 501–513

  • Inga A, Resnick MA . 2001 Oncogene 20: 3409–3419

  • Kaeser MD, Iggo RD . 2002 Proc. Natl. Acad. Sci. USA 99: 95–100

  • Kieser A, Weich HA, Brandner G, Marme D, Kolch W . 1994 Oncogene 9: 963–969

  • Ko LJ, Prives C . 1996 Genes Dev. 10: 1054–1072

  • Lane D . 2001 Nature 414: 25–27

  • Lee YI, Lee S, Das GC, Park US, Park SM . 2000 Oncogene 19: 3717–3726

  • Lin J, Teresky AK, Levine AJ . 1995 Oncogene 10: 2387–2390

  • Ludwig RL, Bates S, Vousden KH . 1996 Mol. Cell. Biol. 16: 4952–4960

  • MacCallum DE, Hupp TR, Midgley CA, Stuart D, Campbell SJ, Harper A, Walsh FS, Wright EG, Balmain A, Lane DP, Hall PA . 1996 Oncogene 13: 2575–2587

  • McLure KG, Lee PW . 1998 EMBO J. 17: 3342–3350

  • Meek DW . 1999 Oncogene 18: 7666–7675

  • Munsch D, Watanabe-Fukunaga R, Bourdon JC, Nagata S, May E, Yonish-Rouach E, Reisdorf P . 2000 J. Biol. Chem. 275: 3867–3872

  • Murphy KL, Dennis AP, Rosen JM . 2000 FASEB J. 14: 2291–2302

  • Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y . 2000 Cell 102: 849–862

  • Offer H, Milyavsky M, Erez N, Matas D, Zurer I, Harris CC, Rotter V . 2001 Oncogene 20: 581–589

  • Pantoja C, Serrano M . 1999 Oncogene 18: 4974–4982

  • Prives C, Hall PA . 1999 J. Pathol. 187: 112–126

  • Reis AM, Cheo DL, Meira LB, Greenblatt MS, Bond JP, Nahari D, Friedberg EC . 2000 Cancer Res. 60: 1571–1579

  • Rodin SN, Holmquist GP, Rodin AS . 1998 Int. J. Mol. Med. 1: 191–199

  • Sage E, Lamolet B, Brulay E, Moustacchi E, Chateauneuf A, Drobetsky EA . 1996 Proc. Natl. Acad. Sci. USA 93: 176–180

  • Saller E, Tom E, Brunori M, Otter M, Estreicher A, Mack DH, Iggo R . 1999 EMBO J. 18: 4424–4437

  • Scharer E, Iggo R . 1992 Nucleic Acids Res. 20: 1539–1545

  • Smith ML, Ford JM, Hollander MC, Bortnick RA, Amundson SA, Seo YR, Deng CX, Hanawalt PC, Fornace Jr AJ . 2000 Mol. Cell. Biol. 20: 3705–3714

  • Smith PD, Crossland S, Parker G, Osin P, Brooks L, Waller J, Philp E, Crompton MR, Gusterson BA, Allday MJ, Crook T . 1999 Oncogene 18: 2451–2459

  • Storici F, Lewis LK, Resnick MA . 2001 Nat. Biotechnol. 19: 773–776

  • Suzuki A, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, Akahane K . 2000 Cell Death Differ. 7: 721–728

  • Szak ST, Mays D, Pietenpol JA . 2001 Mol. Cell. Biol. 21: 3375–3386

  • Takeuchi S, Nakatsu Y, Nakane H, Murai H, Hirota S, Kitamura Y, Okuyama A, Tanaka K . 1998 Cancer Res. 58: 641–646

  • Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, Nakamura Y . 2000 Nature 404: 42–49

  • Thornborrow EC, Manfredi JJ . 1999 J. Biol. Chem. 274: 33747–33756

  • Thornborrow EC, Manfredi JJ . 2001 J. Biol. Chem. 276: 15598–15608

  • van Oosten M, Rebel H, Friedberg EC, van Steeg H, van der Horst GT, van Kranen HJ, Westerman A, van Zeeland AA, Mullenders LH, de Gruijl FR . 2000 Proc. Natl. Acad. Sci. USA 97: 11268–11273

  • Vogelstein B, Lane D, Levine AJ . 2000 Nature 408: 307–310

  • Volker M, Mone MJ, Karmakar P, van Hoffen A, Schul W, Vermeulen W, Hoeijmakers JH, van Driel R, van Zeeland AA, Mullenders LH . 2001 Mol. Cell 8: 213–224

  • Wang YA, Elson A, Leder P . 1997 Proc. Natl. Acad. Sci. USA 94: 14590–14595

  • Wieczorek AM, Waterman JL, Waterman MJ, Halazonetis TD . 1996 Nat. Med. 2: 1143–1146

  • Wijnhoven SW, Kool HJ, Mullenders LH, van Zeeland AA, Friedberg EC, van der Horst GT, van Steeg H, Vrieling H . 2000 Oncogene 19: 5034–5047

  • Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW, Vogelstein B . 1999 Proc. Natl. Acad. Sci. USA 96: 14517–14522

  • Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M . 1995 Nucleic Acids Res. 23: 2584–2592

  • Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, Tom E, Mack DH, Levine AJ . 2000 Genes Dev. 14: 981–993

Download references

Acknowledgements

Our thanks to Dr Antonio Reis for the gift of the tumor RNA samples, to Drs Richard Iggo, Thierry Frebourg, Bert Vogelstein and Moshe Oren for the generous gifts of expression vectors and yeast strains, and to Drs Robbert Slebos, Dmitry Gordenin, Francesca Storici, Gilberto Fronza for advice, helpful discussions and comments on the manuscript. We also thank Russell Daniel and Bonnie Ferguson Darnell for valuable technical support. Alberto Inga was supported by an NIH Courtesy Contract.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael A Resnick.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Inga, A., Nahari, D., Velasco-Miguel, S. et al. A novel p53 mutational hotspot in skin tumors from UV-irradiated Xpc mutant mice alters transactivation functions. Oncogene 21, 5704–5715 (2002). https://doi.org/10.1038/sj.onc.1205779

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205779

Keywords

This article is cited by

Search

Quick links